Antibody Response after ChAdOx1 nCoV-19 Vaccination in Patients with Type 2 Diabetes at Vajira Hospital Antibody Response after Covid-19 Vaccination in T2DM
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: A question exists as to whether people with diabetes can respond effectively to the COVID-19 vaccine. This study aimed to evaluate antibody response after COVID-19 vaccination in patients with type 2 diabetes.
METHODS: This was a cross-sectional analytical study. Two hundred and twelve type 2 diabetes patients were enrolled after receiving a second dose of the ChAdOx1nCoV-19vaccine 3 months previously. Demographic data, medical history, and blood drawn were collected. Antibodies against receptor binding domain (anti-RBD) was investigated in the laboratory department. Other factors that could affect anti-RBD level, i.e. age, gender, BMI, glycemic control, duration of diabetes, and comorbidity, were collected and analyzed.
RESULTS: Among 212 patients with type 2 diabetes 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine, the anti-RBD level mean was 989.56 U/ml. Patients with type 2 diabetes, with or without cardiovascular disease as a comorbidity, had median anti-RBD levels equal to 258 U/ml and 442 U/ml, respectively. The median of anti-RBD levels between groups had statistically significant differences (p-value = 0.021). Age, gender, BMI, duration of diabetes, glycemic control, and other comorbidities showed no statistically significant differences in the median anti-RBD levels.
CONCLUSION: Only patients with type 2 diabetes with cardiovascular disease as a comorbidity showed statistically significant differences in Anti-SARS-CoV-2 response 3 months after receiving a second dose of the ChAdOx1nCoV-19 vaccine. Therefore, patients with diabetes and cardiovascular disease require earlier revaccination to ensure protection against COVID-19 infection.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 2020;23(5):1416-24.
Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Investig 2020;11(5):1104-14.
Pal R, Bhadada SK. Managing common endocrine disorders amid COVID-19 pandemic. Diabetes Metab Syndr 2020;14(5):767-71.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020;36(7):e3319.
Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev Endocr Metab Disord 2021;2 (2):275 96.
CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020;69(13):382-6.
Guan Wj, Ni Zy, Hu Y, Liang Wh, Ou Cq, He Jx, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a primeboost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396(10267):1979-93.
Ali H, Alterki A, Sindhu S, Alahmad B, Hammad M, Al-Sabah S, et al. Robust antibody levels in both diabetic and nondiabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front Immunol 2021; 12:752233.
Marfella R, D’Onofrio N, Sardu C, Scisciola L, Maggi P, Coppola N, et al. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study. Diabetes Obes Metab 2022;24(1):160-5.
Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E, et al. Immunogenicity of BNT162b2 mRNA covid-19 vaccine in patients with cardiovascular disease. J Clin Med 2021;10(23):5498.
Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021;15(2):505-8.